Asset
RELACORILANT
Corcept Therapeutics Incorporated Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (19)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04308590 | phase3 | completed | 2020-07-27 | 2024-09-19 | Corcept Therapeutics | A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas |
| NCT03697109 | phase3 | completed | 2018-11-15 | 2024-04-08 | Corcept Therapeutics | A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome |
| NCT03540836 | phase1 | completed | 2018-05-24 | 2018-07-16 | Corcept Therapeutics | A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants |
| NCT06094725 | phase1 | completed | 2020-01-06 | 2020-12-14 | Corcept Therapeutics | A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant |
| NCT06094712 | phase1 | completed | 2016-04-07 | 2016-04-27 | Corcept Therapeutics | A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 220641 | NDA | CORCEPT THERAPEUTICS INC |
Marketed products (1)
- LIFYORLI (COPACKAGED)